GOLPH3L is a novel prognostic biomarker for epithelial ovarian cancer

Journal of Cancer

Volumn 6, Issue 9, 2015, Pages 893-900

  Feng, Yanling ^a   He, Fan ^b   Wu, Huini ^c   Huang, He ^a   Zhang, Lan ^a   Han, Xian ^d   Liu, Jihong ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d SUN YAT SEN UNIVERSITY   (China)

Author keywords

Epithelial ovarian cancer; GOLPH3L; Prognosis

Indexed keywords

ALBUMIN; CA 125 ANTIGEN; GOLGI PHOSPHOPROTEIN 3; PHOSPHOPROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INHIBITION KINETICS; MAJOR CLINICAL STUDY; OVARY CARCINOMA; OVERALL SURVIVAL; PROTEIN EXPRESSION; UPREGULATION; WESTERN BLOTTING;

EID: 84947746868     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.11865     Document Type: Article

References (18)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics for Hispanics/Latinos, 2012. CA: a cancer journal for clinicians. 2012; 62: 283-98.
2. Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA: a cancer journal for clinicians. 2011; 61: 183-203.
3. Wang JH, Chen XT, Wen ZS, Zheng M, Deng JM, Wang MZ, et al. High expression of GOLPH3 in esophageal squamous cell carcinoma correlates with poor prognosis. PloS one. 2012; 7: e45622.
4. Hu BS, Hu H, Zhu CY, Gu YL, Li JP. Overexpression of GOLPH3 is associated with poor clinical outcome in gastric cancer. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2013; 34: 515-20.
5. Ma Y, Ren Y, Zhang X, Lin L, Liu Y, Rong F, et al. High GOLPH3 expression is associated with a more aggressive behavior of epithelial ovarian carcinoma. Virchows Archiv: an international journal of pathology. 2014; 464: 443-52.
6. Zeng Z, Lin H, Zhao X, Liu G, Wang X, Xu R, et al. Overexpression of GOLPH3 promotes proliferation and tumorigenicity in breast cancer via suppression of the FOXO1 transcription factor. Clinical cancer research: an official journal of the American Association for Cancer Research. 2012; 18: 4059-69.
7. Wang Z, Jiang B, Chen L, Di J, Cui M, Liu M, et al. GOLPH3 predicts survival of colorectal cancer patients treated with 5-fluorouracil-based adjuvant chemotherapy. Journal of translational medicine. 2014; 12: 15.
8. Scott KL, Chin L. Signaling from the Golgi: mechanisms and models for Golgi phosphoprotein 3-mediated oncogenesis. Clinical cancer research: an official journal of the American Association for Cancer Research. 2010; 16: 2229-34.
9. Bell AW, Ward MA, Blackstock WP, Freeman HN, Choudhary JS, Lewis AP, et al. Proteomics characterization of abundant Golgi membrane proteins. The Journal of biological chemistry. 2001; 276: 5152-65.
10. Kunigou O, Nagao H, Kawabata N, Ishidou Y, Nagano S, Maeda S, et al. Role of GOLPH3 and GOLPH3L in the proliferation of human rhabdomyosarcoma. Oncology reports. 2011; 26: 1337-42.
11. Abraham RT. GOLPH3 links the Golgi network to mTOR signaling and human cancer. Pigment cell & melanoma research. 2009; 22: 378-9.
12. Ali MF, Chachadi VB, Petrosyan A, Cheng PW. Golgi phosphoprotein 3 determines cell binding properties under dynamic flow by controlling Golgi localization of core 2 N-acetylglucosaminyltransferase 1. The Journal of biological chemistry. 2012; 287: 39564-77.
13. Ng MM, Dippold HC, Buschman MD, Noakes CJ, Field SJ. GOLPH3L antagonizes GOLPH3 to determine Golgi morphology. Molecular biology of the cell. 2013; 24: 796-808.
14. Silverberg SG. Histopathologic grading of ovarian carcinoma: a review and proposal. International journal of gynecological pathology: official journal of the International Society of Gynecological Pathologists. 2000; 19: 7-15.
15. Fishman DA, Cohen L, Blank SV, Shulman L, Singh D, Bozorgi K, et al. The role of ultrasound evaluation in the detection of early-stage epithelial ovarian cancer. American journal of obstetrics and gynecology. 2005; 192: 1214-21; discussion 21-2.
16. Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). The lancet oncology. 2009; 10: 327-40.
17. Cannistra SA. Cancer of the ovary. New Engl J Med. 2004; 351: 2519-29.
18. Bast RC, Klug TL, Stjohn E, Jenison E, Niloff JM, Lazarus H, et al. A Radioimmunoassay Using a Monoclonal-Antibody to Monitor the Course of Epithelial Ovarian-Cancer. New Engl J Med. 1983; 309: 883-7.